

氏名	所属	職名	取得学位	専門分野	主な論文・著作・業績
世良田 聡	創薬・医療機器開発部門	教授	博士（理学）	分子生物学 標的治療 診断マーカー	①Uchida S., Serada S., Suzuki Y., Funajima E., Kitakami K., Dobashi K., Tamatani S., Sato Y., Beppu T., Ogasawara K., Naka T. Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma. Neoplasia. 50:100982.(2024) ②Munekage E., Serada S., Tsujii S., Yokota K., Kiuchi K., Tominaga K., Fujimoto M., Kanda M., Uemura S., Namikawa T., Nomura T. Murakami T., Hanazaki K., Naka T. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. Neoplasia. 23(9):939-950. (2021) ③Serada S., Fujimoto M., Terabe F, Iijima H., Shinzaki S., Matsuzaki S., Ohkawara T., Nezu R., Nakajima S., Kobayashi T., Plevy SE., Takehara T., Naka T. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis. 18(11):2169-79. (2012) ④Serada S., Fujimoto M., Ogata A., Terabe F, Hirano T., Iijima H., Shinzaki S., Nishikawa T., Ohkawara T., Iwahori K., Ohguro N., Kishimoto T., Naka T. iTRAQ-based proteomic identification of leucine rich alpha 2 glycoprotein (LRG) as a novel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis. 69:770-774. (2010) ⑤Serada S., Fujimoto M., Mihara M., Koike N., Ohsugi O., Nomura S., Yoshida H., Nishikawa T., Terabe F., Ohkawara T., Takahashi T., Ripley B., Kimura A., Kishimoto T., Naka T. IL-6 blockade inhibits the induction of myelin antigen specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 105: 9041-9046. (2008)

田中 十志也	創薬・医療機器開発部門	教授	博士（学術）	薬系化学および創薬科学関連 医化学関連 病態医化学関連	①Yang C., Arai M., Ariyanto EF, Zhang J., Lubis DM., Ito R., Xie S., Nitta M., Kawashima F, Ishitsuka T., Yang T., Suzuki T., Komatsu T., Sagae H., Jin H., Takahashi H., Kobayashi E., Wei Y., Liu B., Choi H., Wada Y., Tanaka T., Osawa T., Kimura H., Kodama T., Aburatani H., Tachibana M., Shinkai Y., Inagaki T., Soga T., Osborne TF., Yoneshiro T., Matsumura Y., Sakai J. Glucose-activated JMJD1A drives visceral adipogenesis via α-ketoglutarate-dependent chromatin remodeling. Cell Rep., 44: 116060 (2025). ②Ito R., Xie S., Tumenjargal M., Sugahara Y., Yang C., Takahashi H., Arai M., Inoue S., Uchida A., Nakano K., Choi H., Yang G., Zhao Y., Yamaguchi R., Jin H., Sagae H., Wada Y., Tanaka T., Kimura H., Kodama T., Aburatani H., Takeda K., Inagaki T., Osborne TF., Yoneshiro T., Matsumura Y., Sakai J. Mitochondrial biogenesis in white adipose tissue mediated by JMJD1A-PGC-1 axis limits age-related metabolic disease. iScience. 27: 109398 (2024). ③Takahashi H., Yang G., Yoneshiro T., Abe Y., Ito R., Yang C., Nakazono J., Okamoto-KM., Uchida A., Arai M., Jin H., Choi H., Tumenjargal M., Xie S., Zhang J., Sagae H., Zhao Y., Yamaguchi R., Nomura Y., Shimizu Y., Yamada K., Yasuda S., Kimura H., Tanaka T., Wada Y., Kodama T., Aburatani H., Zhu MS., Inagaki T., Osborne TF., Kawamura T., Ishihama Y., Matsumura Y., Sakai J. MYPT1-PP1β phosphatase negatively regulates both chromatin landscape and co-activator recruitment for beige adipogenesis. MYPT1-PP1β phosphatase negatively regulates both chromatin landscape and co-activator recruitment for beige adipogenesis. Nat Commun., 13: 5715 (2022). ④Makino Y., Kamiyama Y., Brown JB., Tanaka T., Murakami R., Teramoto Y., Goto T., Akamatsu S., Terada N., Inoue T., Kodama T., Ogawa O., Kobayashi T. Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1. Commun Biol., 5: 299 (2022). ⑤Matsumura Y., Ito R., Yajima A., Yamaguchi R., Tanaka T., Kawamura T., Magoori K., Abe Y., Uchida A., Yoneshiro T., Hirakawa H., Zhang J., Arai M., Yang C., Yang G., Takahashi H., Fujihashi H., Nakaki R., Yamamoto S., Ota S., Tsutsumi S., Inoue S., Kimura H., Wada Y., Kodama T., Inagaki T., Osborne TF., Aburatani H., Node K., Sakai J. Spatiotemporal dynamics of SETD5-containing NCoR-HDAC3 complex determines enhancer activation for adipogenesis. Nat Commun., 12: 7045 (2021).
西塚 哲	創薬・医療機器開発部門	特任教授	博士（医学）	システム医学 腫瘍学 定量生物学	①Abe M, Hiraki H, Tsuyukubo T, Ono S, Maekawa S, Tamura D, Yashima-Abo A, Kato R, Fujisawa H, Iwaya T, Woong-Yang Park , Idogawa M, Tokino T, Obara W, <u>Nishizuka SS</u>: The clinical validity of urinary pellet DNA monitoring for the diagnosis of recurrent bladder cancer/J Mol Diagn. 2024 Apr;26(4):278-291. ②Koizumi Y, Ahmad S, Ikeda M, Yashima-Abo A, Espina G, Sugimoto R, Sugai T, Iwaya T, Tamura G, Koeda K, Liotta LA, Takahashi F, <u>Nishizuka SS</u>; Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy.Northern Japan Gastric Cancer Study Consortium. J Natl Cancer Inst. 2022 Aug 8;114(8):1149-1158 ③Yaegashi M, Iwaya T, Sasaki N, Fujita M, Ju Z, Siwak D, Hachiya T, Sato K, Endo F, Kimura T, Otsuka K, Sugimoto R, Sugai T, Liotta L, Lu Y, Mills GB, Nakagawa H, <u>Nishizuka SS</u>: Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling/ Br J Cancer. 2021 Apr;124(9):1556-1565. ④Iwaya T, Endo F, Takahashi F, Tokino T, Sasaki Y, <u>Nishizuka SS</u>: Frequent Tumor Burden Monitoring of Esophageal Squamous Cell Carcinoma With Circulating Tumor DNA Using Individually Designed Digital Polymerase Chain Reaction/ Gastroenterology. 2021 Jan;160(1):463-465.e4. ⑤特許第6544783号「名称：がんの診断のためのプローブ/プライマーライブラリー」

鈴木 悠地	創薬・医療機器開発部門	特任教授	博士(医学)	消化器病学 再生医療 腫瘍学 分子生物学	①Suzuki Y, Serada S, Yamashita M, Kawabata K, Takahashi T, Obata K, Jo A, Funajima E, Doki Y, Naka T. Assessing efficacy of anti-glypican-1 antibody-drug conjugate as potential therapeutic approach for gastric cancer. Gastric Cancer. 2025;28:1201-1212. ②Suzuki Y, Tasaki M, Kakisaka K, Nishiya M, Nomura T, Nakao M, Sugawara E, Takikawa Y, Ueda M. Possible transmission of leukocyte chemotactic factor 2 amyloidosis after interpopulational liver transplantation. Amyloid. 2024;31:232-234. ③Suzuki Y, Kakisaka K, Sato T, Mikami R, Abe H, Sasaki T, Takikawa Y. Tc-99m GSA scintigraphy within the first 3 days after admission as an early predictor of outcome in severe acute liver injury. Sci Rep. 2021;11:12518. ④Suzuki Y, Kakisaka K, Suzuki A, Takahara T, Sasaki T, Sato T, Yonezawa T, Nitta H, Takikawa Y. A Lille model for predicting the response of severe alcoholic hepatitis to corticosteroid treatment in Japanese patients. Hepatol Res. 2019;49:758-764 ⑤Suzuki Y, Katagiri H, Wang T, Kakisaka K, Kume K, Nishizuka SS, Takikawa Y. Ductular reactions in the liver regeneration process with local inflammation after physical partial hepatectomy. Lab Invest. 2016;96:1211-1222.
真柳 平	創薬・医療機器開発部門	講師	博士（生命科学）	神経科学 分子生物学 細胞生物学	①Mayanagi T, Sobue K. Social Stress-Induced Postsynaptic Hyporesponsiveness in Glutamatergic Synapses Is Mediated by PSD-Zip70-Rap2 Pathway and Relates to Anxiety-Like Behaviors. (2020) Front Cell Neurosci. 13:564. ②Mayanagi T, Yasuda H, Sobue K. PSD-Zip70 Deficiency Causes Prefrontal Hypofunction Associated with Glutamatergic Synapse Maturation Defects by Dysregulation of Rap2 Activity. (2015) J. Neurosci. 35(42):14327-14340. ③Fukumoto K, Morita T, Mayanagi T, Tanokashira D, Yoshida T, Sakai A, Sobue K. (2009) Detrimental effect of glucocorticoids on neuronal migration during brain development. Mol. Psychiatry 14(12):1119-1131. ④Mayanagi T, Morita T, Hayashi K, Fukumoto K, Sobue K (2008) Glucocorticoid receptor-mediated expression of Caldesmon regulates cell migration via the reorganization of the actin cytoskeleton. J. Biol. Chem. 283(45):31183-31196. ⑤Morita T, Mayanagi T, Sobue K (2007) Dual roles of myocardin-related transcription factors in epithelial-mesenchymal transition via slug induction and actin remodeling. J. Cell. Biol. 179(5):1027-1042.
阿保 亜紀子	創薬・医療機器開発部門	講師	博士（医学）	人体病理学 （血液病理） 実験病理学	① Yoshida T, Muramatsu H, Ishikawa S, Oikawa K, Asakura Y, Miura S, <u>Yashima-Abo A</u> , Nishizuka SS, Wakamatsu M, Terui K, Toki T, Ito E, Endo M, Akasaka M: Molecular Remission Confirmed by Monitoring a PTPN11 Mutation in Myeloid Leukemia of Down Syndrome Treated With Reduced-Intensity Stem Cell Transplantation: A Case Report. Pediatr Blood Cancer. 73(2). (2026) ② Suzuki M, <u>Yashima-Abo A</u> , Ehara S, Ito S, Satoh T: Magnetic resonance imaging findings of intravascular large B-cell lymphoma mimicking fasciitis of the thigh: A case report. J Clin Exp Hematop. 65(2):115–120. (2025) （Corresponding author） ③ <u>阿保亜紀子</u> ：骨髓肉腫．加留部謙之輔，倉田盛人 編．腫瘍病理鑑別診断アトラス『造血器腫瘍 第2版』．文光堂，東京．（2026）（分担執筆） ④ 圭陵会学術振興会共同研究助成（研究代表者） 研究課題：びまん性大細胞型B細胞リンパ腫予後規定因子としての骨髓浸潤の検討－空間トランスクリプトーム解析による腫瘍・骨髓微小環境の解析－．（2026） ⑤ 科学研究費助成事業 基盤研究（C）（研究代表者） 研究課題：悪性リンパ腫の骨髓浸潤治療後再発に及ぼす腫瘍クローンの検出．（2024）

クウィック あゆみ	創薬・医療機器開発部門	助教	社会健康医学修士 (専門職)	分子生物学	①山下 将司, 世良田 聡, クウィック あゆみ, 大河原 知治, 村田 興則, 細野 祐司, 伊藤 いづみ, 中屋 流石, 舟嶋 英治, 鈴木 悠地, 藤本 穰, 諏訪部 章, 仲 哲治. シェーグレン症候群の疾患活動性評価におけるLRGの有用性の検討. 第33回日本リウマチ学会北海道・東北支部学術集会. (2023) ②Fujimoto M., Hosono Y., Serada S., Suzuki Y., Ohkawara T., Murata O., Quick A., Suzuki K., Kaneko Y., Takeuchi T., Naka T. Leucine-rich α 2-glycoprotein as a useful biomarker for evaluating disease activity in rheumatoid arthritis. Mod Rheumatol. 34(5):1072-1075. (2024)
開 勇人	創薬・医療機器開発部門	助教	博士（農学）	分子細胞生物学 生理学	①Nakai T, Kitahata Y, <u>Hiraki H</u> , Nakamura Y, Motobayashi H, Takemoto N, Hyo T, Sato M, Ojima T, Hayata K, Goda T, Kitadani J, Tominaga S, Hayami S, Miyamoto A, Yamaue H, Iwaya T, Nishizuka SS, Kawai M. Ann Surg Oncol. 2026 Aug;33(8):7688-7698. doi: 10.1245/s10434-026-19757-0 (2026) ②Sasaki T, <u>Hiraki H</u> . Yashima-Abo-A. Nagashima H, Endo F, Yaegashi M. Miura S. Obata K. Yanagawa N, Itamochi H. Shirota H. Iwaya T. Nishizuka SS. Comprehensive Genome Profiling-InitiatedTumor-Informed Circulating Tumor DNA Monitoring forPatients With Advanced Cancer. Cancer Sci. (2025) ③Abe M, <u>Hiraki H</u> , Tsuyukubo T, Ono S, Maekawa S, Tamura D, Yashima-Abo A, Kato R, Fujisawa H, Iwaya T, Park WY, Idogawa M, Tokino T, Obara W, Nishizuka SS. The Clinical Validity of Urinary Pellet DNA Monitoring for the Diagnosis of Recurrent Bladder Cancer. JMD. doi.org/10.1016/j.jmoldx.2024.01.006 (2024) ④文部科学省学術研究助成基金助成金（若手研究）課題名：腫瘍内遺伝子変異不均一性に対応した超高感度ctDNAモニタリング方法の開発. 2024年（代表者） ⑤特許PCT国際出願 PCT/JP2022/43189: がんの診断のためのプローブ／プライマーライブラリー